William Frank Iv Hulse Sells 81,446 Shares of MiMedx Group, Inc. (NASDAQ:MDXG) Stock

MiMedx Group, Inc. (NASDAQ:MDXG) CAO William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the transaction, the chief accounting officer now directly owns 494,774 shares of the company’s stock, valued at $3,859,237.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

William Frank Iv Hulse also recently made the following trade(s):

• On Thursday, March 13th, William Frank Iv Hulse sold 54,596 shares of MiMedx Group stock. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG opened at $7.92 on Friday. The firm has a 50 day moving average of $8.45 and a 200 day moving average of $7.81. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of 14.40 and a beta of 1.97. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. The company had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. On average, research analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Hedge Funds Weigh In On MiMedx Group

A number of hedge funds have recently modified their holdings of MDXG. First Light Asset Management LLC bought a new position in shares of MiMedx Group in the fourth quarter worth approximately $32,168,000. Norges Bank purchased a new position in shares of MiMedx Group in the fourth quarter worth $4,020,000. JPMorgan Chase & Co. lifted its holdings in shares of MiMedx Group by 133.1% in the fourth quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company’s stock worth $6,668,000 after buying an additional 395,739 shares in the last quarter. Meros Investment Management LP purchased a new position in shares of MiMedx Group in the fourth quarter worth $3,801,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of MiMedx Group by 484.2% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company’s stock worth $3,487,000 after buying an additional 300,433 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.